Deason Sues Xerox To Block Deal With Fujifilm

Much ado surrounds the prospective merger of Xerox Corp with Japan’s Fujifilm Holdings joint venture, Fuji Xerox. Two Xerox shareholders, Darwin Deason and Carl Icahn, have asserted that the $6.1 billion merger inexplicably favors Fuji and severely undervalues the U.S. photocopier manufacturer. Claiming a failure of duty to its shareholders, Deason is suing Xerox to block the merger.

Although a partnership between the Japanese and American giants has subsisted since 1962, with current agreements dating back as recently as 2001, Deason argues that a previously unrevealed “crown jewel” lock-up right exists wherein should Xerox sell a 30% share of their stock to another party, Fuji is granted control over Xerox’s intellectual property and manufacturing rights in the Asia-Pacific market

As stated in Deason’s complaint, “The ‘end game’ for Xerox – a sale to Fuji – was decided 17 years ago with this undisclosed ‘crown jewel’ lock-up right granted to Fuji, and shareholders had absolutely no clue.”

However, Xerox, insists that Mr. Icahn and Mr. Deason were both aware of the agreement details, going on to state, “These documents have since been publicly disclosed. For any of them to assert that these agreements were ‘shrouded in mystery’ is disingenuous, at best.” Xerox also pronounced, “The agreement is a binding legal document that cannot be simply wished away, renegotiated or dissolved because Mr. Icahn and Mr. Deason desire it so,”

Owners of a combined 15.2% share in Xerox, both Icahn and Deason have asked their fellow shareholders to free “the company from the shackles of the Fuji Xerox joint venture.” Xerox, maintaining that the merger is in the best interest of the company, countered in a recent letter to shareholders (who still have to approve the deal) that abandoning the merger would be exceedingly expensive, requiring a total supply chain rebuild that would take indeterminate time to execute.

Follow us on social media for the latest updates in B2B!

Image

Latest

pcp
PCP Attribution Analysis
May 22, 2025

Dr. Sam Ambewadikar, RVP and Medical Director at Anthem National Accounts, joins Brent to unpack the power of primary care attribution analysis—a tool he helped pioneer to spotlight the clinical and financial impact of members not having an established PCP. Drawing from his background as a practicing pediatrician and claims analytics leader, Dr. Sam shares…

Read More
sydney health
Sydney Health Demo
May 22, 2025

In this episode, Christina Firouztash, Executive Advisor of Digital Solutions at Anthem, gives a dynamic walkthrough of the Sydney Health app—Anthem’s flagship digital member experience. Christina showcases how Sydney delivers personalized, simple, and equitable navigation across benefits, including virtual care, pharmacy, financial transparency, and social services access. From contextual chatbots and ID card access to…

Read More
pharmacy
Pharmacy Part 1
May 22, 2025

In this episode, Brent chats with Katie Brennan, National Sales Director at CarelonRx, about making pharmacy benefits more accessible, consistent, and member-friendly. Katie spotlights Carelon new advanced home delivery model, which brings the pharmacy counter—and the pharmacist—into the member’s home. With fewer retail pharmacies offering extended hours and many patients lacking reliable transportation, CarelonRx is…

Read More
inclusive care
Inclusive Care
May 22, 2025

Sammy Gonzalez, Regional Vice President at Elevance Health, joins Brent for a deeply personal and impactful conversation on health equity and inclusive care. Sammy shares a powerful story of medical misdiagnosis tied to cultural assumptions, underscoring how bias—even unintentional—can hinder care quality. He highlights Elevance’s work to improve diversity in provider networks, enhance cultural competency,…

Read More